Eikon Therapeutics (EIKN) vs SAB Biotherapeutics (SABS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Eikon Therapeutics is the larger company by market cap ($256.8 million vs $253.1 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EIKN | SABS |
|---|---|---|
| Share price | $4.74 | $2.81 |
| Market cap | $256.84M | $253.15M |
| 1-day change | -0.42% | -3.44% |
| YTD return | — | -24.87% |
| 1-year return | — | -28.86% |
| 5-year return | — | -97.32% |
| EPS (TTM) | $-7.86 | $-1.35 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $0 |
| Revenue growth (YoY) | — | -100.00% |
| Net income (latest FY) | — | $13.27M |
| 52-week high | $17.40 | $5.15 |
| 52-week low | $4.72 | $2.44 |
| Distance from 52-week high | -72.76% | -45.44% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +406.33% | +314.23% |
| Average volume | 560.40K | 633.60K |
| Shares outstanding | 54.19M | 90.09M |
| Employees | 384 | 86 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Eikon Therapeutics
EIKN stock →Eikon Therapeutics, Inc., operates as a clinical biopharmaceutical company in the United States. It develops medicines to address serious unmet medical needs.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 384 employees
About SAB Biotherapeutics
SABS stock →SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 86 employees
EIKN vs SABS FAQ
Which is bigger, Eikon Therapeutics or SAB Biotherapeutics?
Eikon Therapeutics (EIKN) is larger, with a market capitalization of $256.84M compared with $253.15M for SAB Biotherapeutics (SABS).
Are Eikon Therapeutics and SAB Biotherapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.